Kathryn F. Mileham
Experienced in Sideroblastic Anemia

Dr. Kathryn F. Mileham

Hematology | Oncology
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Sideroblastic Anemia
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathryn Mileham is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Mileham is rated as an Experienced provider by MediFind in the treatment of Sideroblastic Anemia. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Squamous Cell Lung Carcinoma. Dr. Mileham is currently accepting new patients.

Her clinical research consists of co-authoring 41 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Medical University Of South Carolina
Residency
Vanderbilt University Medical Center, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine, Medical Oncology
Fellowships
Vanderbilt University Medical Center, Hematology/Oncology
Hospital Affiliations
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute (Thoracic-Pulmonary)
1021 Morehead Medical Drive, Building 2, Suite 30500, Charlotte, NC 28204
Other Locations
Atrium Health Levine Cancer Institute
1021 Morehead Medical Drive, Charlotte, NC 28204

Additional Areas of Focus

Dr. Mileham has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer
Prostate Cancer
B-Cell Lymphoma
Interstitial Lung Disease
Colorectal Cancer
Leukemia
Multiple Myeloma
Adult T-Cell Leukemia
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Erlotinib, Gefitinib, Osimertinib
Study Phase: Phase 3
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drugs: EGF816, INC280, Nivolumab
Study Phase: Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

41 Total Publications

Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.
Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.
Journal: Future oncology (London, England)
Published: November 11, 2025
Similar Doctors
Distinguished in Sideroblastic Anemia
Dr. Matthew M. Rees
Hematology Oncology | Hematology | Oncology
Distinguished in Sideroblastic Anemia
Dr. Matthew M. Rees
Hematology Oncology | Hematology | Oncology
201 E Grover St, 
Shelby, NC 
 (39.9 miles away)
980-487-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Rees is a Hematologist Oncology specialist and a Hematologist in Shelby, North Carolina. Dr. Rees is rated as a Distinguished provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Lynch Syndrome, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Rees is currently accepting new patients.

Mauricio Pineda
Advanced in Sideroblastic Anemia
Dr. Mauricio Pineda
Hematology | Oncology
Advanced in Sideroblastic Anemia
Dr. Mauricio Pineda
Hematology | Oncology

Atrium Health Levine Cancer Institute

100 Medical Park Drive, NE, Suite 110, 
Concord, NC 
 (21.5 miles away)
704-403-1370
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mauricio Pineda is a Hematologist and an Oncologist in Concord, North Carolina. Dr. Pineda is rated as an Advanced provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Thrombocytopenia, Hairy Cell Leukemia (HCL), Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma. Dr. Pineda is currently accepting new patients.

Advanced in Sideroblastic Anemia
Dr. James G. Wall
Hematology Oncology | Hematology | Oncology
Advanced in Sideroblastic Anemia
Dr. James G. Wall
Hematology Oncology | Hematology | Oncology
340 Jake Alexander Blvd W, Ste 101, 
Salisbury, NC 
 (36.5 miles away)
704-403-4900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

James Wall is a Hematologist Oncology specialist and a Hematologist in Salisbury, North Carolina. Dr. Wall is rated as an Advanced provider by MediFind in the treatment of Sideroblastic Anemia. His top areas of expertise are Paget Disease of the Breast, Multiple Myeloma, Myelodysplastic Syndrome (MDS), and Familial Prostate Cancer. Dr. Wall is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mileham's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile